Skip to main content
Erschienen in: Die Diabetologie 3/2021

11.03.2021 | Typ-2-Diabetes | DDG Praxisempfehlungen

Diabetes und Fettleber

verfasst von: Prof. Dr. med. Norbert Stefan, Prof. Dr. Dr. h. c. med. univ. Michael Roden

Erschienen in: Die Diabetologie | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://​www.​deutsche-diabetes-gesellschaft.​de/​behandlung/​leitlinien) befinden sich alle PDF zum kostenlosen Download. …
Literatur
1.
Zurück zum Zitat M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRef M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRef
2.
Zurück zum Zitat Younossi ZM (2019) Non-alcoholic fatty liver disease—A global public health perspective. J Hepatol 70:531–544CrossRef Younossi ZM (2019) Non-alcoholic fatty liver disease—A global public health perspective. J Hepatol 70:531–544CrossRef
3.
Zurück zum Zitat Eigentler T, Lomberg D, Machann J et al (2020) Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med 172:836–837CrossRef Eigentler T, Lomberg D, Machann J et al (2020) Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med 172:836–837CrossRef
4.
Zurück zum Zitat Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904CrossRef Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904CrossRef
5.
Zurück zum Zitat Stefan N, Häring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7:313–324CrossRef Stefan N, Häring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7:313–324CrossRef
6.
Zurück zum Zitat Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7:684–694CrossRef Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7:684–694CrossRef
7.
Zurück zum Zitat Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14:32–42CrossRef Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14:32–42CrossRef
8.
Zurück zum Zitat European Association for the Study of the Liver (EASL), European European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140CrossRef European Association for the Study of the Liver (EASL), European European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140CrossRef
9.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357CrossRef Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357CrossRef
10.
Zurück zum Zitat Bril F, McPhaul MJ, Caulfield MP et al (2019) Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 67:303–311CrossRef Bril F, McPhaul MJ, Caulfield MP et al (2019) Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 67:303–311CrossRef
11.
Zurück zum Zitat Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654.e1–9CrossRef Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654.e1–9CrossRef
12.
Zurück zum Zitat Adams LA, Anstee QM, Tilg H et al (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153CrossRef Adams LA, Anstee QM, Tilg H et al (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153CrossRef
Metadaten
Titel
Diabetes und Fettleber
verfasst von
Prof. Dr. med. Norbert Stefan
Prof. Dr. Dr. h. c. med. univ. Michael Roden
Publikationsdatum
11.03.2021
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 3/2021
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-021-00744-w

Weitere Artikel der Ausgabe 3/2021

Die Diabetologie 3/2021 Zur Ausgabe

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.